Skip to main content
NAUT
NASDAQ Industrial Applications And Services

Nautilus Biotechnology Extends Cash Runway Through 2027, Reports Reduced Losses and Commercialization Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.89
Mkt Cap
$365.022M
52W Low
$0.62
52W High
$3.08
52W Position info
366% above low
Off High info
6.2% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

NAUT has more than doubled off its 52-week low of $0.62.

Summary

Nautilus Biotechnology reported reduced net losses and operating expenses for Q4 and FY 2025, while also announcing a cash runway through 2027 and significant progress towards its late 2026 commercial launch.


Key Events · Earnings and Guidance · NAUT

  • Reduced Net Losses

    The company reported a net loss of $13.8 million for Q4 2025, an improvement from $17.6 million in Q4 2024, and $59.0 million for FY 2025, down from $70.8 million in FY 2024.

  • Decreased Operating Expenses

    Operating expenses for Q4 2025 decreased by 23% year-over-year to $15.4 million, and by 18% for FY 2025 to $66.8 million, reflecting improved efficiency.

  • Extended Cash Runway

    Nautilus Biotechnology holds $156.1 million in cash, cash equivalents, and investments as of December 31, 2025, projecting sufficient resources to fund operations through 2027.

  • Commercialization Progress

    The company launched an Iterative Mapping Early Access Program in January 2026 and unveiled the Nautilus Voyager™ platform, targeting a full commercial launch in late 2026.


Analysis · NAUT · Industrial Applications And Services

This 8-K filing provides a significant positive update for Nautilus Biotechnology, a development-stage company. The reported reduction in net losses and operating expenses for both the fourth quarter and full fiscal year 2025 demonstrates improved financial management and efficiency. Crucially, the company announced it has sufficient cash, cash equivalents, and investments to fund operations through 2027, significantly de-risking its near-term financial outlook and removing a major overhang for investors. This extended cash runway provides stability as the company continues to advance its single-molecule proteome analysis platform towards a planned commercial launch in late 2026, supported by the successful initiation of its Early Access Program and new strategic collaborations.

At the time of this filing, NAUT was trading at $2.89 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $365M. The 52-week trading range was $0.62 to $3.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAUT - Latest Insights

NAUT
Jul 28, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $1.04 info
Change: -$0.160 (-13%) info
Market Cap: $131.073M info
NAUT
Jul 28, 2026, 8:10 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.51
Real-time Price: $1.04 info
Change: -$0.470 (-31%) info
Market Cap: $131.073M info
NAUT
Jul 27, 2026, 7:29 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.04 info
Change: -$0.680 (-40%) info
Market Cap: $131.073M info
NAUT
Jun 30, 2026, 5:13 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.87
Real-time Price: $1.04 info
Change: -$0.830 (-44%) info
Market Cap: $131.073M info
NAUT
Jun 04, 2026, 4:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $2.68
Real-time Price: $1.04 info
Change: -$1.64 (-61%) info
Market Cap: $131.073M info